Health Care [ 12/12 ] | Biotechnology [ 69/75 ]
NASDAQ | Common Stock
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally.
It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.
The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc"RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants.
The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech BiopharmaL. L.C. to develop and commercialize its commercial product EVOMELA.
It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH.
CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 16, 24 | -0.55 Increased by +28.57% | -0.63 Increased by +12.70% |
| May 14, 24 | -0.71 Decreased by -57.78% | -0.05 Decreased by -1.32 K% |
| Mar 28, 24 | -0.45 Increased by +68.75% | -0.24 Decreased by -87.50% |
| Nov 14, 23 | -0.35 Increased by +7.89% | -0.56 Increased by +37.50% |
| Aug 11, 23 | -0.77 Decreased by -37.50% | -0.50 Decreased by -54.00% |
| May 17, 23 | -0.45 Increased by +25.00% | -0.64 Increased by +29.69% |
| Mar 30, 23 | -1.44 Decreased by -260.00% | -0.37 Decreased by -289.19% |
| Nov 14, 22 | -0.38 Increased by +45.71% | -0.46 Increased by +17.39% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 3.41 M Decreased by -77.66% | -9.53 M Increased by +48.48% | Decreased by -279.50% Decreased by -130.59% |
| Dec 31, 23 | 6.09 M Decreased by -60.08% | -5.46 M Increased by +70.47% | Decreased by -89.66% Increased by +26.03% |
| Sep 30, 23 | 8.84 M Decreased by -13.46% | -4.63 M Decreased by -19.77% | Decreased by -52.44% Decreased by -38.40% |
| Jun 30, 23 | 9.82 M Increased by +14.55% | -10.24 M Decreased by -33.32% | Decreased by -104.27% Decreased by -16.39% |
| Mar 31, 23 | 15.26 M Increased by +68.38% | -18.50 M Decreased by -90.55% | Decreased by -121.21% Decreased by -13.16% |
| Dec 31, 22 | 15.26 M Increased by +66.62% | -18.50 M Decreased by -230.21% | Decreased by -121.21% Decreased by -98.18% |
| Sep 30, 22 | 10.21 M Increased by +25.90% | -3.87 M Increased by +62.15% | Decreased by -37.89% Increased by +69.93% |
| Jun 30, 22 | 8.57 M Increased by +19.70% | -7.68 M Decreased by -10.57% | Decreased by -89.58% Increased by +7.63% |